Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9962275 | 0.85 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL15887374 | 0.84 | GABRA1 (0.36) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL19200362 | 0.83 | — | — | |
| SCHEMBL7745010 | 0.79 | ALDH1A1 (0.43) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL25465411 | 0.78 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL25759799 | 0.78 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL25759801 | 0.78 | GABRA1 (0.38) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL7693244 | 0.75 | HTR2C (0.33) | CA1CA2CYP1A2TSHRHTR2C | |
| SCHEMBL25761404 | 0.74 | GABRA1 (0.34) | GABRA1GABRG2GABRB3GABRB2FAAH | |
| SCHEMBL26733744 | 0.73 | ALDH1A1 (0.39) | GABRA1GABRG2GABRB3GABRB2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669034-B2 | 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| US-9115065-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses | Kineta, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9067873-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | Kineta Four, LLC (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8664274-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8658697-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8642596-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses | SIGA TECHNOLOGIES, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130261087-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES | SIGA TECHNOLOGIES INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8410149-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410149-B2 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7994221-B2 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SIGA TECHNOLOGIES, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | SIGA TECHNOLOGIES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | SIGA TECHNOLOGIES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118505-A1 | Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | SORD, GBA1, GK | GABRA1 4370/4885GABRG2 4452/4885GABRB3 4291/4885 |
| US-20140275037-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | GABRA1 4008/4885GABRG2 4286/4885GABRB3 4294/4885 |
| US-20100256096-A1 | Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses | GBA1, SORD, GK | GABRA1 4437/4885GABRG2 4574/4885GABRB3 4573/4885 |
| US-20140378681-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | GABRA1 4008/4885GABRG2 4286/4885GABRB3 4294/4885 |
| US-20130261087-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES | SORD, GBA1, GK | GABRA1 4344/4885GABRG2 4452/4885GABRB3 4302/4885 |
| US-20090203675-A1 | Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses | GBA1, GK, GCK | GABRA1 3987/4885GABRG2 4293/4885GABRB3 4333/4885 |
| US-20120022027-A1 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES | GBA1, GK, GCK | GABRA1 4008/4885GABRG2 4286/4885GABRB3 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.